Abstract | PURPOSE: PATIENTS AND METHODS: Twenty-five cases of MCC were treated at the London Regional Cancer Center between 1987 and 1997. Thirteen cases treated with chemotherapy were reviewed with 191 cases from the literature. RESULTS: At presentation, 24 patients had localized skin lesions (stage I) and one had locoregional involvement (stage II). Among the nine cases with recurrent nodal disease, six had chemotherapy as a component of salvage treatment. They were all free of disease at a median of 19 months (range, 12 to 37 months). In contrast, two patients who had salvage radiotherapy alone died of disease. Overall survival (OS) and disease-free survival (DFS) were 59% and 43%, respectively, at two years. Median OS and DFS were 29 months (range, 1 to 133 months) and 9 months (range, 1 to 133 months), respectively. Nodal disease developed in 12 (50%) of 24 patients with stage I disease, and distant metastases developed in six (25%) of 24. Including those from the literature, there were 204 cases treated with chemotherapy. Cyclophosphamide/ doxorubicin (or epirubicin)/ vincristine combination +/- prednisone was the most commonly used chemotherapy regimen (47 cases), with an overall response rate of 75.7% (35.1% complete, 35. 1% partial, and 5.4% minor responses). Etoposide/ cisplatin (or carboplatin) was the next most commonly used regimen (27 cases), with an overall response rate of 60% (36% complete and 24% partial responses). The difference in response rate was not statistically significant (P =.19). Among the 204 cases, there were seven (3.4%) toxic deaths. CONCLUSION: Chemoradiation for locally recurrent or advanced disease may be an option for patients with a good performance status.
|
Authors | P T Tai, E Yu, E Winquist, A Hammond, L Stitt, J Tonita, J Gilchrist |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 18
Issue 12
Pg. 2493-9
(Jun 2000)
ISSN: 0732-183X [Print] United States |
PMID | 10856110
(Publication Type: Journal Article, Review)
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Merkel Cell
(drug therapy, pathology, radiotherapy)
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Humans
- Karnofsky Performance Status
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Skin Neoplasms
(drug therapy, pathology, radiotherapy)
- Treatment Outcome
|